The impact of dasatinib on pregnancy outcomes

Jorge E. Cortes, Elisabetta Abruzzese, Ekaterina Chelysheva, Mausumee Guha, Nicola Wallis, Jane F. Apperley

Research output: Contribution to journalArticle

Abstract

Prolonged survival in patients with chronic myeloid leukemia treated with BCR-ABL1-targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy-related outcomes in dasatinib-treated patients or their partners reported to Bristol-Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46/78 dasatinib-treated women (59%) and 33/69 partners of dasatinib-treated men (48%). Fifteen women (33%) delivered a normal infant; 18 (39%) and 8 (17%) had an elective or spontaneous abortion; and 5 (11%) had an abnormal pregnancy. There were 7 reports of fetal/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91%) infants fathered by dasatinib-treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo-fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks.

Original languageEnglish (US)
Pages (from-to)1111-1115
Number of pages5
JournalAmerican Journal of Hematology
Volume90
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Pregnancy Outcome
Embryonic and Fetal Development
Dasatinib
Encephalocele
Hydrops Fetalis
Pregnancy
Spontaneous Abortion
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Health Personnel
Protein-Tyrosine Kinases
Fertility
Clinical Trials
Parturition
Kidney
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Cortes, J. E., Abruzzese, E., Chelysheva, E., Guha, M., Wallis, N., & Apperley, J. F. (2015). The impact of dasatinib on pregnancy outcomes. American Journal of Hematology, 90(12), 1111-1115. https://doi.org/10.1002/ajh.24186

The impact of dasatinib on pregnancy outcomes. / Cortes, Jorge E.; Abruzzese, Elisabetta; Chelysheva, Ekaterina; Guha, Mausumee; Wallis, Nicola; Apperley, Jane F.

In: American Journal of Hematology, Vol. 90, No. 12, 01.12.2015, p. 1111-1115.

Research output: Contribution to journalArticle

Cortes, JE, Abruzzese, E, Chelysheva, E, Guha, M, Wallis, N & Apperley, JF 2015, 'The impact of dasatinib on pregnancy outcomes', American Journal of Hematology, vol. 90, no. 12, pp. 1111-1115. https://doi.org/10.1002/ajh.24186
Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. American Journal of Hematology. 2015 Dec 1;90(12):1111-1115. https://doi.org/10.1002/ajh.24186
Cortes, Jorge E. ; Abruzzese, Elisabetta ; Chelysheva, Ekaterina ; Guha, Mausumee ; Wallis, Nicola ; Apperley, Jane F. / The impact of dasatinib on pregnancy outcomes. In: American Journal of Hematology. 2015 ; Vol. 90, No. 12. pp. 1111-1115.
@article{90974ac8093544da88f6ce273c0929ed,
title = "The impact of dasatinib on pregnancy outcomes",
abstract = "Prolonged survival in patients with chronic myeloid leukemia treated with BCR-ABL1-targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy-related outcomes in dasatinib-treated patients or their partners reported to Bristol-Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46/78 dasatinib-treated women (59{\%}) and 33/69 partners of dasatinib-treated men (48{\%}). Fifteen women (33{\%}) delivered a normal infant; 18 (39{\%}) and 8 (17{\%}) had an elective or spontaneous abortion; and 5 (11{\%}) had an abnormal pregnancy. There were 7 reports of fetal/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91{\%}) infants fathered by dasatinib-treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo-fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks.",
author = "Cortes, {Jorge E.} and Elisabetta Abruzzese and Ekaterina Chelysheva and Mausumee Guha and Nicola Wallis and Apperley, {Jane F.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/ajh.24186",
language = "English (US)",
volume = "90",
pages = "1111--1115",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - The impact of dasatinib on pregnancy outcomes

AU - Cortes, Jorge E.

AU - Abruzzese, Elisabetta

AU - Chelysheva, Ekaterina

AU - Guha, Mausumee

AU - Wallis, Nicola

AU - Apperley, Jane F.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Prolonged survival in patients with chronic myeloid leukemia treated with BCR-ABL1-targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy-related outcomes in dasatinib-treated patients or their partners reported to Bristol-Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46/78 dasatinib-treated women (59%) and 33/69 partners of dasatinib-treated men (48%). Fifteen women (33%) delivered a normal infant; 18 (39%) and 8 (17%) had an elective or spontaneous abortion; and 5 (11%) had an abnormal pregnancy. There were 7 reports of fetal/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91%) infants fathered by dasatinib-treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo-fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks.

AB - Prolonged survival in patients with chronic myeloid leukemia treated with BCR-ABL1-targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy-related outcomes in dasatinib-treated patients or their partners reported to Bristol-Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46/78 dasatinib-treated women (59%) and 33/69 partners of dasatinib-treated men (48%). Fifteen women (33%) delivered a normal infant; 18 (39%) and 8 (17%) had an elective or spontaneous abortion; and 5 (11%) had an abnormal pregnancy. There were 7 reports of fetal/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91%) infants fathered by dasatinib-treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo-fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks.

UR - http://www.scopus.com/inward/record.url?scp=84954220288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954220288&partnerID=8YFLogxK

U2 - 10.1002/ajh.24186

DO - 10.1002/ajh.24186

M3 - Article

C2 - 26348106

AN - SCOPUS:84954220288

VL - 90

SP - 1111

EP - 1115

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -